Prognostic relationship of metabolic profile obtained of melanoma B16F10

Biomedicine and Pharmacotherapy

Volumn 67, Issue 2, 2013, Pages 146-156

  Fedele, Thiago Antonio ^a,b   Galdos Riveros, Alvaro Carlos ^a,b   Jose de Farias e Melo, Homero ^c   Magalhães, Alviclér ^d   Maria, Durvanei Augusto ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

1HNMR; Apoptosis; Melanoma; Metabolomic analysis; Proliferation

Indexed keywords

ACETIC ACID; ALANINE; ASPARTIC ACID; BIOLOGICAL MARKER; CASPASE 3; CHOLINE; CREATINE; CYCLIN D1; GLYCEROL; INOSITOL; LACTIC ACID; LIPID; PHOSPHORYLCHOLINE; TAURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASPHYXIA; AUTOPSY; CANCER STAGING; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL KINETICS; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH CURVE; INOCULATION; M PHASE CELL CYCLE CHECKPOINT; MELANOMA; MELANOMA CELL; METABOLIC PARAMETERS; METABOLITE; METABOLOMICS; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLINE; CREATINE; CYCLIN D1; DISEASE PROGRESSION; ENERGY METABOLISM; FEMALE; MELANOMA, EXPERIMENTAL; METABOLOME; METABOLOMICS; MICE; MICE, INBRED C57BL; NECROSIS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875373573     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.013     Document Type: Article

References (33)

1. Mazurek S., Zwerschke W., Jansen-Dürr P., Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001, 20:6891-6898.
2. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927, 8:519-530.
3. Deberardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
4. Lunt S.Y., Vander Heiden M.G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011, 27:441-464.
5. Morvan D., Demidem A., Papon J., De Latour M., Madelmont J.C. Melanoma tumors acquire new phospholipid metabolism phenotype under cystemustine treatment as revealed by proton HRMAS NMR spectroscopy of intact tumor samples. Cancer Res 2002, 62:1890-1897.
6. Morvan D., Demidem A., Papon J., Madelmont J.C. Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl-nitrosourea: demonstration of phospholipid metabolism alterations. Magn Reson Med 2003, 49:241-248.
7. Hawkins E.D., Hommel M., Turner M.L., Battye F., Markham J., Hodgkin P.D. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat Protoc 2007, 2:2057-2067.
8. 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal Biochem 1994, 220:284-296.
9. Bollard M.E., Stanley E.G., Lindon J.C., Nicholson J.K., Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005, 18:143-162.
10. Craig A., Cloarec O., Holmes E., Nicholson J.K., Lindon J.C. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem 2006, 78:2262-2267.
11. 1HNMR metabonomics. Anal Chem 2006, 78:4281-4290.
12. Ferreira A.K., Meneguelo R., Pereira A., Mendonça Filho O.R., Chierice G.O., Maria D.A. Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental study. Anticancer Res 2012, 32(1):95-104.
13. Ferreira A.K., Meneguelo R., Marques F.L., Radin A., Filho O.M., Neto S.C., et al. Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase. Biomed Pharmacother 2012, 6:541-548.
14. Kroemer G. Mitochondria in cancer. Oncogene 2006, 25:4630-4632.
15. Jackowski S. Cell cycle regulation of membrane phospholipid metabolism. J Biol Chem 1996, 271:20219-20222.
16. Jackowski S. Coordination of membrane phospholipid synthesis with the cell cycle. J Biol Chem 1994, 269:3858-3867.
17. Szwergold B.S., Shaller C., Kappler F., Aiken N.R., Stoyanova R., Brown T.R. Effects of mitogenic stimulation on choline and phosphatidylcholine metabolism in mammalian cells. 4th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Abstract 1996, 268.
18. Griffiths J.R., Cady E., Edwards R.H.T., McCready V.R., Wilkie D.R., Wiltshaw E. 31P-NMR studies of a human tumour in situ. Lancet 1983, 321:1435-1436.
19. Proietti E., Carpinelli G., Di Vito M., Belardelli F., Gresser I., Podo F. 31P nuclear magnetic resonance analysis of interferon induced alterations of phospholipid metabolism in interferon sensitive and interferon-resistant Friend leukemia cell tumors in mice. Cancer Res 1986, 46:2849-2857.
20. Fu Y.M., Yu Z.X., Ferrans V.J., Meadows G.G. Tyrosine and phenylalanine restriction induces G0/G1 cell cycle arrest in murine melanoma in vitro and in vivo. Nutr Cancer 1997, 29:104-113.
21. Fu Y.M., Zhang H., Ding M., Li Y.Q., Fu X., Yu Z.X., et al. Specific amino acid restriction inhibits attachment and spreading of human melanoma via modulation of the integrin/focal adhesion kinase pathway and actin cytoskeleton remodeling. Clin Exp Metastasis 2004, 21:587-598.
22. Abdallah R.M., Starkey J.R., Meadows G.G. Dietary restriction of tyrosine and phenylalanine: inhibition of metastasis of three rodent tumors. J Natl Cancer Inst 1987, 78:759-766.
23. Elstad C.A., Meadows G.G., Abdallah R.M. Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction. Clin Exp Metastasis 1990, 8:393-416.
24. Norris J.R., Meadows G.G., Massey L.K., Starkey J.R., Sylvester D.M., Liu S.Y. Tyrosine- and phenylalanine-restricted formula diet augments immunocompetence in healthy humans. Am J Clin Nutr 1990, 51:188-196.
25. Furuya Y., Ohta S., Yasuda K., Ito H. Enhanced expression of cyclin-dependent kinase inhibitor in apoptosis of androgen-independent prostatic cancer line induced by calcium ionophore. Anticancer Res 1997, 17:2391-2394.
26. Yoshioka T., Wada T., Uchida N., Maki H., Yoshida H., Ide N., et al. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 1998, 58:2583-2587.
27. Oxnard G.R., Schwartz L.H. Early changes in tumor size in patients treated for advanced stage non-small cell lung cancer do not correlate with survival. Cancer 2010, 116:1615.
28. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002, 52:72-91.
29. Gatenby R.A., Gillies R.J. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 2007, 39:1358-1366.
30. Heiden Vander M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
31. 1HNMR visible lipids in the life and death of cells. Trends Biochem Sci 2000, 25:357-362.
32. 1H MRSI. J Magn Reson Imaging 2002, 16:464-476.
33. Zaider M., Zelefsky M.J., Lee E.K., Zakian K.L., Amols H.I., Dyke J., et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000, 47:1085-1096.